



When the source
of bleeding is **less**
than clear,

SURGIFLO™
Haemostatic Matrix

helps restore
critical visibility.^{1,2}

ETHICON
PART OF THE JOHNSON & JOHNSON FAMILY OF COMPANIES

Shaping
the future
of surgery

Thrombin prepared inside or outside the sterile field

When difficult-to-access bleeding limits your visibility, **SURGIFLO™ works fast to make things clear.**




SURGIFLO™ helps achieve visibility fast during critical moments.

Haemostasis achieved within 60 seconds^{3*}


Shown to be effective at achieving haemostasis in cases of **mild oozing, moderate flowing blood, and pulsatile, spurting bleeding**^{4†}

*SURGIFLO™ was tested 16 times divided equally on 4 pigs.
†In animal models.


Thicker next generation matrix^{*6} is ideal for difficult-to-access areas.




Epidural gutter bleeding



Tumour bed bleeding



Difficult-to-access cardiac bleeding



Solid organ bleeding

Adherent

Stays in place even during active bleeding⁴

Precise

Malleable tip allows precise placement in difficult-to-access areas, cavities, and crevices

Better packing versus SPONGOSTAN™

Greater conformability and more tissue surface contact⁷

*When compared to previous generation of Surgiflo (MS0009).

**In blind testing,
surgeons prefer
the consistency
of SURGIFLO™
Haemostatic Matrix
over Floseal.*5**

*Testing conducted with 101 US surgeons using SURGIFLO™ versus Floseal.

NOTE: Claim applies to surgeons with a preference.

†Each product was prepared following Instructions for Use.


‡ Average variation across 3 replicates. Based on in vitro viscosity testing of SURGIFLO™ 8 mL and Floseal Haemostatic Matrix 5 mL.

**SURGIFLO™ remains flowable
throughout lengthy, complex
procedures^{2,8}**


The premoistened gelatin mixes uniformly with the thrombin to ensure the matrix retains consistency throughout the length of the syringe and for up to 8 hours^{2,8}

Variation in Matrix Flowability⁸

(As measured immediately after preparation^{†‡})




Get the dual effect of SURGIFLO™ with Thrombin.



1. For bleeding that is difficult to access or when you cannot see the source of the bleeding, SURGIFLO™'s next generation thicker matrix*⁶ allows precise placement, reaches into irregular crevices, conforms to the tissue and stays in place during active bleeding.⁴



2. The flowable gelatin matrix provides an environment for platelets to adhere and aggregate within, building on the patient's natural coagulation cascade. Enhancing the tamponade of the gelatin matrix, the thrombin component of SURGIFLO™ acts as a catalyst and activates the patient's endogenous fibrinogen, accelerating clot formation².



3. Once bleeding has ceased, excess SURGIFLO™ can be gently irrigated away so as not to disturb the new clot. When used in appropriate amounts, SURGIFLO™ is absorbed completely within 4-6 weeks.²

Take action.
Stop the bleeding.

*When compared to previous generation of Surgiflo (MS0009).

Thrombin
prepared
inside or
outside
the sterile
field

Prepare the way you prefer.

Thrombin preparation **inside or outside**
the sterile field²

Focus on the procedure.
SURGIFLO™'s
preparation is simple.

Faster to prepare versus Floseal^{9*†}

Vial adapter designed to eliminate needle sticks



*SURGIFLO™ Haemostatic Matrix (8 mL) versus Floseal Haemostatic Matrix (5 mL - CE version).


†Testing conducted with 24 nurses preparing both products

NOTE: Total preparation time was recorded from opening the box until the product is ready and the surgeon can apply product

As surgery time increases, so does **the value** of SURGIFLO™ Haemostatic Matrix.

In a peer-reviewed article from the *Journal of Medical Economics*, a research team from the Wharton School of Business found that use of SURGIFLO™ resulted in similar clinical outcomes and lower associated costs than Floseal.¹⁰

Annual savings (**US dollars**) per hour of surgery duration per number of procedures¹⁰



In a 4-hour surgery, use of SURGIFLO™ resulted in a **\$150 reduction in flowable costs.**¹⁰

Ordering Information

SURGIFLO™ Haemostatic Matrix

Ordering Code	Size	Package
MS0012	8 mL SURGIFLO™ Haemostatic Matrix Kit with Thrombin	1 Kit
MS0010	8 mL SURGIFLO™ Haemostatic Matrix	1 Kit
MS1995	34 cm Endoscopic Applicator	Box of 6

**For more information or to place an order,
contact your local Ethicon sales professional
For additional information, visit www.ethicon.com***

Please always refer to the Instructions for Use / Package Insert which come with the device for the most current and complete instructions.

References: **1.** Data on file, Ethicon, Inc: S-Factors Insight Research and Next Steps Meeting. **2.** SURGIFLO™ Hemostatic Matrix Kit with Thrombin [instructions for use]. Somerville, NJ: Ethicon, Inc; 2014. **3.** Evaluation of the dose response curve for hemostatic efficacy of SURGIFLO® next generation mixed with thrombin: report NG_162. October 10, 2013. **4.** Pilot evaluation comparing the time-to-hemostasis and hemostatic efficacy of Surgiflo®, next generation Surgiflo®, and Floseal (all prepared with thrombin) in an acute punch biopsy porcine spleen model: Final report 11-071. June 7, 2011. **5.** SURGIFLO® claims research: report on the results. August 1, 2014. **6.** Gelatin Paste Density in SURGIFLO Next Generation Product: Memorandum on Gelatin Density. Ethicon, Inc.; 03 March 2011. **7.** Evaluation of the conformability of SURGIFLO® (pre-filled flowable hemostat) vs. SURGIFOAM®. **8.** Measurements of viscosity and Thrombin activity of SURGIFLO 2993 as compared to FLOSEAL over time. April 7, 2013. **9.** Time Motion Study Statistical Summary. Felton Willis; July 13, 2015. **10.** David G, Sangtaeck L, Gunnarsson L, Delatore P, Kocharian R. Similar patient outcomes yet different hospital costs between flowable hemostatic agents. J Med Econ 2015; 1:11.

Floseal is a trademark of Baxter, Inc.

Johnson & Johnson Medical Pty Ltd. 1-5 Khartoum Road, North Ryde, NSW, 2113.
Tel: (02) 9815 4000 Fax: (02) 9815 3782 Toll Free: 1800 257 210
064602-200906 September 2020
EMA Copy Approval: EMA-BIOSURGERY-15-0119
©Ethicon Inc, 2015

Johnson & Johnson (NZ) Ltd 507 Mt Wellington
Highway, Mt Wellington, Auckland, 1060



ETHICON
PART OF THE *Johnson & Johnson* FAMILY OF COMPANIES

Shaping
the future
of surgery

To contact your **ETHICON®** representative, please call customer service in Australia on 1800 252 194

*This website/app is not owned by Johnson & Johnson Medical Pty. Ltd. or Johnson & Johnson (NZ) Ltd., and we do not review or control the content of this website/app. Products discussed on this website/app may not be approved for use, or may be approved for different indications in your country. Before using any medical device, review all relevant Instructions for Use, Package Inserts or Summary of Product Characteristics. We do not endorse the use or promotion of unapproved products or indications. Any demonstrations of approved medical devices should be considered as information only and are not a surgical training guide.